Studies of the effectiveness of a new antiserotonin agent in patients with the carcinoid syndrome are described. Five of the seven patients tested had significant and objective evidence of improvement of symptoms. The clinical usefulness of this class of agents (antiserotonin) in the management of carcinoid patients is reemphasized.
Mengel CE, Lotito CA. A New Antiserotonin in the Carcinoid Syndrome. Arch Intern Med. 1968;121(6):507–510. doi:10.1001/archinte.1968.03640060021004